Article Text

Download PDFPDF
Pharmacological interventions
There has been very little progress in treating or preventing antipsychotic-induced tardive dyskinesia
  1. Peter van Harten
  1. Correspondence to Maastricht University School for Mental Health and Neuroscience Division Neuroscience, Maastricht 6229 ER, The Netherlands; pnvanharten{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on : Bergman H, Walker DM, Nikolakopoulou A, et al. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess 2017;21:1-218.

What is already known on this topic

Tardive dyskinesia (TD) is a relatively frequent side effect of long-term use of antipsychotics and there is conflicting evidence if the incidence of TD is lower with second-generation antipsychotics (excluding clozapine), compared with first-generation antipsychotics. Until now there is no evidence-based algorithm to prevent or to treat TD.

Methods of the study

This systematic review1 evaluated any intervention for treating or preventing deterioration of symptoms of antipsychotic-induced TD in adult patients. Included were all relevant studies, regardless of language, about adults who had used antipsychotic drugs for ≥3 months and in whom the antipsychotic doses had been stable for at least 1 month. The authors included 112 randomised trials and eight prospective cohort studies. Seventy-nine separate interventions were the focus of the trials, whereas prospective cohort studies focused on comparing different strategies for antipsychotics. These were grouped into three broad categories: 1. Reducing antipsychotic dose. 2. Switching antipsychotic drug. (3) Adjunctive treatments in …

View Full Text


  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.